scispace - formally typeset
M

Michael S. Ewer

Researcher at University of Texas Health Science Center at Houston

Publications -  6
Citations -  3027

Michael S. Ewer is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Cardiac imaging & Ejection fraction. The author has an hindex of 3, co-authored 6 publications receiving 2372 citations. Previous affiliations of Michael S. Ewer include Duke University.

Papers
More filters
Journal ArticleDOI

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Juan Carlos Plana, +26 more
- 01 Sep 2014 - 
TL;DR: The noninvasive evaluation of LVEF has gained importance, and notwithstanding the limitations of the techniques used for its calculation, has emerged as the most widely used strategy for monitoring the changes in cardiac function, both during and after the administration of potentially car- diotoxic cancer treatment.
Journal ArticleDOI

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Juan Carlos Plana, +26 more
- 01 Oct 2014 - 
TL;DR: The non-invasive evaluation of LVEF has gained importance, and notwithstanding the limitations of the techniques used for its calculation, has emerged as the most widely used strategy for monitoring the changes in cardiac function, both during and after the administration of potentially cardiotoxic cancer treatment.
Journal ArticleDOI

Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline

Saro H. Armenian, +21 more
- 10 Mar 2017 - 
TL;DR: Recommendations for prevention and monitoring of cardiac dysfunction in survivors of adult-onset cancers were developed by an expert panel with multidisciplinary representation using a systematic review of meta-analyses, randomized clinical trials, observational studies, and clinical experience.
Journal ArticleDOI

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

Alvaro Moreno-Aspitia, +41 more
- 01 May 2021 - 
TL;DR: In this paper, the authors present pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial and show that T+L did not significantly improve DFS and OS over T alone, both with chemotherapy, and therefore cannot be recommended for adjuvant treatment of early-stage HER2-positive breast cancer.
Proceedings ArticleDOI

Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

E. de Azambuja, +15 more
- 15 Feb 2017 -